Research Lab

The inaugural Virtual Epigenetic Therapeutic Target Summit will provide the industry’s definitive guide to translating epigenetic medecines into clinically effective treatments. Expect to hear the latest clinical trial results, including where epigenetic-targeted therapies have been applied as monotherapy or in a combinatorial approach (including with immunotherapies) in the treatment of hematologic malignancies. There will also be further discussion on how this class of therapy has exhibited viable therapeutic potential for solid tumours.

From selecting the best target for each disorder indication (including beyond oncology), to monitoring and limiting off-target toxicity and identifying the right patient population, ETT Summit will cover the full medecine development spectrum for epigenetic therapies in all disorder areas.

Join 75 of your peers from biotechnology and pharmaceutical companies to share challenges and unite over a common goal: to harness the potential of epigenetics and find effective treatments for patients in need.